Biophysical Assays Screening Hits Small Molecule 
Sygnature Discovery
JUNE 17, 2024
Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities. Sygnature Discovery’s Biophysical Assay Development Capabilities: 1.
Drug Target Review
NOVEMBER 1, 2023
The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We have several exciting projects in various stages of discovery, but a small-molecule drug that is causing a lot of excitement at the moment is Capivasertib.
Expert insights. Personalized for you.
52 
Let's personalize your content